Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Substance Related Disorders

Renal Insufficiency

Drug-Related Side Effects and Adverse Reactions

Chemically-Induced Disorders

Kidney Diseases

Urologic Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Male Urogenital Diseases

Micronutrients

All Drugs and Chemicals

Antineoplastic Agents

Vitamins

Vitamin A

Retinol palmitate

Antibodies

Immunoglobulins

Immunoglobulin G

Immunoglobulins, Intravenous

Cystatins

Retinol

blood test for renal biomarkers (uromodulin,Neutrophil gelatinase-associated lipocalin, beta-trace protein, creatinine, cystatin C)

blood test for renal biomarkers

urine test for renal biomarkers (uromodulin, alpha-1 microglobulin, retinol-binding protein, Neutrophil gelatinase-associated lipocalin (NGAL), beta-trace protein, cylinder, albumin, immunoglobulin G (IgG), transferrin, creatinine)

urine test for renal biomarkers

Marc Pfister, Prof MD

This study is to investigate blood and urine kidney injury markers (especially Uromodulin) in pediatric cancer patients treated with nephrotoxic chemotherapy. Uromodulin is a marker to detect and monitor tubular injury and renal function.

Study to Evaluate Blood and Urine Kidney Injury Markers to Facilitate Early Detection of Renal Adverse Drug Events in Pediatric Cancer Patients Treated With Nephrotoxic Chemotherapy

Pilot Study to Evaluate Blood and Urine Kidney Injury Markers to Facilitate Early Detection of Renal Adverse Drug Events in Pediatric Cancer Patients Treated With Nephrotoxic Chemotherapy (Kid-MaCare Oncology)

Change in serum uromodulin levels (ng/ml)

Change in urine uromodulin levels (ng/ml)

Stiftung für Krebskranke Kinder

University Hospital, Basel, Switzerland

Behaviors and Mental Disorders

Quality of Life

Proton therapy

Do Hoon Lim, MD, PhD

Jeong Il Yu, MD

The study aim of this study is to evaluate the effect of proton therapy on quality of life and long-term normal tissue toxicities of the pediatric cancer patients. Based on these results, the predictive model of long-term normal tissue toxicities, survival, and quality of life could be recognized. Risk-adapted treatment strategy based on the predictive model in pediatric cancer patients could be established.

Registry for Analysis of Quality of Life, Normal Organ Toxicity and Survival of Pediatric Patients Treated With Proton Therapy

Samsung Medical Center

Professor

Nervous System Diseases

Symptoms and General Pathology

Sleep Deprivation

Eligible patients will be approached for enrollment after their first night in the hospital (i.e.: not on day of admission). Patient/parent will be asked to complete a brief questionnaire describing the child's general sleep habits prior to admission. The parent and/or child will then be asked to complete a questionnaire describing sleep while in the hospital; this in-hospital sleep questionnaire will be obtained for 3 consecutive nights after enrollment, or until discharge, whichever is soonest. A subgroup of patients (between the ages of 5 and 18) will be invited to participate in an additional aspect of the study, where they wear an actigraph (a small device that looks like a watch) for up to 72 hours. This device reliably measures sleep by monitoring the child's motion. This will be used to relate sleep perception to more objective measures of sleep as provided by actigraphy.

Pre-hospital sleep questionnaire completed (Brief Infant Sleep Questionnaire (BISQ)7 in children 0-3 years old; Children's Sleep Habits Questionnaire (CSHQ)8 in children 4 years and older). Subsequent Day(s):

In-hospital sleep questionnaire completed between one and three times per subject (Sleep at MSK questionnaire (SAM), adapted from Sleep in a Children's Hospital (SinCH)9 by Dr. Lisa Meltzer). (Patients will be observed for up to 3 consecutive nights in total).

questionnaires

This device reliably measures sleep by monitoring the child's motion.

actigraph

Chani Traube, MD

The investigators want to better understand how children sleep at night at MSKCC, so that the investigators can learn how to improve the sleeping environment.

Sleep in Hospitalized Children at MSKCC

A Pilot Study: Sleep in Hospitalized Children With Cancer and Related Diseases

Johns Hopkins University

Weill Medical College of Cornell University

Memorial Sloan Kettering Cancer Center

Nausea

Vomiting

Signs and Symptoms, Digestive

Anti-Inflammatory Agents

Antiemetics

Gastrointestinal Agents

Dexamethasone

Fosaprepitant

Aprepitant

Dexamethasone acetate

Granisetron

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Neurokinin-1 Receptor Antagonists

Substance P

Neurokinin A

Neurotransmitter Agents

Serotonin

Serotonin 5-HT3 Receptor Antagonists

Patients received intravenous Granisetron plus dexamethasone followed by fosaprepitant infusion

Patients received intravenous Granisetron plus dexamethasone followed by oral aprepitant

Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO. When used with fosaprepitant, dexamethasone dose was halved.

Fosaprepitant: 4 mg/kg IV

fosaprepitant

Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO. When used with aprepitant, dexamethasone dose was halved.

Oral aprepitant: D1：Powder for suspension 3.0 mg/kg (up to 125 mg),D2，D3：Powder for suspension 2.0 mg/kg (up to 80 mg).

aprepitant

Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO.

Granisetron plus dexamethasone

Li-Ting Yu, MD

Yi-Jin Gao

Children aged 2-12 years scheduled to receive moderately or highly emetogenic chemotherapy were randomly assigned to arm-A (fosaprepitant) or arm-B (aprepitant). Children recruited to arm-A received intravenous granisetron plus dexamethasone followed by fosaprepitant infusion. Children recruited to arm-B received the same drugs as those given to children in arm-A, except that fosaprepitant was substituted with aprepitant. Granisetron and dexamethasone were given continuously until 48 hours after completion of chemotherapy. The primary end point of the study was to determine the proportion of patients who achieved a CR, defined as no vomiting, no retching, and no use of rescue medication, the proportion of patients who achieved a CR during the acute phase (0-24 hours) after administration of the last dose of chemotherapy. Secondary end points were the proportion of patients who achieved a CR during the 24-120 hours (delayed phase) and overall after administration of the last dose of chemotherapy.

Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients

Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients：A Superiority Design, Phase III Randomized Trial

The primary end point was complete remission rates in the acute phase. Complete Remission was defined as no vomiting, no retching, and no use of rescue medication

Complete Remission rates in the delayed and overall phases

All of the adverse reactions of aprepitant and fosaprepitant during the study.

Shanghai Children's Medical Center

Tissue Doppler ultrasound on pediatric patients

Doppler ultrasound

Reham M Farghally

Duaa M Raafat

Reham Farghally

Duaa Raafat

Tissue Doppler assessment of right ventricular function in newly diagnosed pediatric cancer patients underwent chemotherapy in South Egypt Cancer Institute.

The incidence of cancer is always increasing and it is predicted that the incidence will increase to 45% by 2030(1). The introduction of new chemotherapeutic agents significantly improved survival, but also revealed large spectrum of cardiotoxicity manifestations (2). There are many factors that increase the risk of cardiotoxicity caused by different chemotherapeutic agents, such as type of chemotherapy, cumulative dose, concomitant or previous radiotherapy, and comorbidities (3). Chemotherapeutic regimens which contain anthracyclines, cyclophosphamide, fluorouracil, cisplatin, taxanes and trastuzumab cause early and late cardiotoxicity (4).

The majority of published studies are focused on left ventricle dysfunction in patients receiving cardiotoxic chemotherapy. However, the right ventricle has been ignored for a long time and a little attention has been directed to show the effect of chemotherapy on right ventricle function. Right ventricle dysfunction is associated with increased morbidity and mortality in many cardiovascular diseases (5). The structure of cardiomyocytes and blood supply between the left and right ventricles are similar. Given the smaller mass and fewer myofibrils of right ventricle, chemotherapy may theoretically cause a more significant impact on it (6).

The right ventricle has a complex geometric shape which includes smooth muscular inflow, outflow and a trabecular apical region so echocardiographic assessment of right ventricle is difficult (7).

M-mode echocardiography, two-dimensional echocardiography, conventional Doppler echocardiography, and myocardial Doppler tissue imaging are all used to evaluate right ventricular function and provide accurate prognostic information especially when used in combination

Tissue Doppler Assessment of Right Ventricle Function in Pediatrics Underwent Chemotherapy

Tissue Doppler Assessment of Right Ventricular Function in Newly Diagnosed Pediatric Cancer Patients Underwent Chemotherapy in South Egypt Cancer Institute

The correlation between echocardiographic parameters of the RV, measured with transthoracic echocardiography before and after chemotherapy

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study to Evaluate Blood and Urine Kidney Injury Markers to Facilitate Early Detection of Renal Adverse Drug Events in Pediatric Cancer Patients Treated With Nephrotoxic Chemotherapy	NCT04308642	Kidney Impairme...	blood test for ... urine test for ...	- 18 Years	University Hospital, Basel, Switzerland
Registry for Analysis of Quality of Life, Normal Organ Toxicity and Survival of Pediatric Patients Treated With Proton Therapy	NCT02644993	Pediatric Cance...	Proton therapy	- 18 Years	Samsung Medical Center
Sleep in Hospitalized Children at MSKCC	NCT02836041	Pediatric Cance...	questionnaires actigraph	0 Months - 18 Years	Memorial Sloan Kettering Cancer Center
Registry for Analysis of Quality of Life, Normal Organ Toxicity and Survival of Pediatric Patients Treated With Proton Therapy	NCT02644993	Pediatric Cance...	Proton therapy	- 18 Years	Samsung Medical Center
Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients	NCT04873284	Chemotherapy In... Pediatric Cance...	fosaprepitant aprepitant Granisetron plu...	2 Years - 12 Years	Shanghai Children's Medical Center
Sleep in Hospitalized Children at MSKCC	NCT02836041	Pediatric Cance...	questionnaires actigraph	0 Months - 18 Years	Memorial Sloan Kettering Cancer Center
Tissue Doppler Assessment of Right Ventricle Function in Pediatrics Underwent Chemotherapy	NCT04831359	Pediatric Cance...	Doppler ultraso...	1 Year - 16 Years	Assiut University

Spots Global Cancer Trial Database for pediatric cancer patients